The View from Hyderabad
The boom town of Hyderabad is the center of India’s pharmaceutical industry, and this was where I met with representatives from two Indian pharmaceutical companies to discuss topics such as economies of scale in pharmaceutical production—the special capacity of the Indian pharma sector—licenses with foreign multinationals such as Gilead and prospects for new research and development. This chapter argues that those who anticipate a simple takeover by “multinational” companies of “Indian” companies, which are in fact also multinational, simplify what are complex and surprising emergences negotiated by quite powerful India-based corporate actors. The chapter also examines the first two patented drugs developed in India under the new patent regime, an anti-malarial medication and a cancer drug, and considers whether new research by Indian companies will focus on medical problems affecting low income countries or on products for high income markets.